- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque psoriasis Moderate to severe hidradenitis suppurativa
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 371KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 54KB)
Adalimumab – November 2023
Adalimumab: Injection 40 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen; Hadlima®
Last updated
1 March 2024